TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01333969

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Preconditioning
Description: In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
Study: NCT03880019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT00002663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
Study: NCT03880019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT02592863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take placebo 3 times per day for 12 weeks
Study: NCT04962113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TUBE BATH
Description: Wrap Tube Baht (immersion)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TUBE BATH
Description: Wrap Tube Baht (immersion)
Study: NCT00899301

Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: Tissue, urine and blood collection.

Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: Tissue, urine and blood collection.
Study: NCT04632654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME)
Description: A total of 7 weekly intervention sessions will occur in a period of 6 weeks. Week 0 is a setup session conducted at the participant's home, including equipment set up, safety instruction, personalized exergame prescription development, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 1 and 2 are coaching sessions delivered by the interventionist using the FaceTime application in iPad, including exergame minutes and prescription review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Week 3 is a progress session conducted at the participant's home. The personalized exergame prescription will be adjusted. This session also will include exergame minutes review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 4 and 5 are the same as weeks 1 and 2. Week 6 is the final session. Exergame platform will be picked up at the participant's home.
Study: NCT04726527

Intervention type: DRUG
Intervention: Florbetapir F 18
Description: A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.

Intervention type: DEVICE
Intervention: Positron Emission Tomography
Description: PET Scan for brain imaging
Study: NCT00002663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
Study: NCT02176343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL
Description: Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Study: NCT04003038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: Receive wound care with NPWT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Care Management
Description: Receive wound care with a standard dressing (bandage)
Study: NCT06571890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narcotrend bispectral index anaesthesia monitor
Description: A bispectral index anaesthesia monitor collects simplified EEG via forehead electrodes and displays an index of 0-100, where an index of 40-60 is considered optimal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mdoloris Anaesthesia Nociception Monitor
Description: A heart rate variability-based nociception monitor collects ECG-signal from electrodes on the patient's chest and displays an index of 0-100 where an index below 50 is considered nociceptive.
Study: NCT03093415

Intervention type: DRUG
Group type: OTHER
Intervention: elbasvir-grazoprevir (50 mg/100 mg)
Description: 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: elbasvir-grazoprevir (50 mg/100 mg)
Description: 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: elbasvir-grazoprevir (50 mg/100 mg)
Description: 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
Study: NCT03421002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour.
Study: NCT01810731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (QIV)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Polio Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Dose QIV
Study: NCT01696071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 mcg qd
Description: 2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 mcg bid
Description: 2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
Study: NCT03314194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant Based Diet
Description: Plant Based Diet for 4 Days Compared to Habitual Diet
Study: NCT00579137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath -1H
Description: Given intravenous on Days -8,-7, and -6~Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients \>15 kg to 30 kg the dose 5 mg; for patients \> 30 kg the dose is 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenous on Days -8,-7,-6,-5, and -4~Dose is 30 mg/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD45
Description: Given intravenous over 6 hours on Days -5,-4,-3, and -2~Dose is 400 microgram/kg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: stem cells are infused on day 0
Study: NCT01980147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maCBT
Description: Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
Study: NCT03685149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide Pill
Description: Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flecainide Pill
Description: Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
Study: NCT01655277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Adductor Canal Block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Adductor Canal Block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Femoral Nerve Block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Femoral Nerve Block
Study: NCT04025320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraneural Facilitation
Description: Intraneural Facilitation utilizes three manual holds. Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium. Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated. Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold. The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle. This treatment will take 50-60 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center. The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy. The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on. The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf. A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
Study: NCT04289493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language and functional communication therapy
Description: 17 therapy sessions in which the patients will be asked to dubb words or sentences from television series previously considered functionally meaningful for them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language and functional communication therapy
Description: 17 therapy sessions in which the patients will be asked to dubb words or sentences from television series previously considered functionally meaningful for them.
Study: NCT00997763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V
Description: everolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CYPHER
Description: sirolimus-eluting stent
Study: NCT01628952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane
Description: PIA coelioscopic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curare
Description: IAP coelioscopic
Study: NCT00989495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brace
Description: Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brace
Description: Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
Study: NCT04400331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study: NCT04355312

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Use of Indocyanine Green in laparoscopic ovarian cystectomy
Description: During intraperitoneal cystectomy or Plasmajet destruction of the cyst, as a benign organic cyst requiring surgical treatment, peroperatively, at the end of the cystectomy procedure, injection by the anesthetist on a peripheral venous route of a bolus of Indocyanine green diluted 0.2mg / kg. Installation of the SPIES camera system (KARL STORZ GmbH \& Co.KG, Tuttlingen, Germany).~Evaluation of the degree of fluorescence at the location of cystectomy or destruction of the cyst.~A fluorescence score between 0 and 4 (on the model of a Likert scale) will be used for the evaluation of fluorescence.~A second reading of the Likert scale results will be carried out by a second inspector so that the score is as objective as possible. Then, second evaluation technique realized by the METAMORPH software, which will assign a raw and objective score according to the fluorescence visualized.
Study: NCT02686697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnosine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Cognitive Training for 2 weeks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Training
Description: Cognitive Training for 2 weeks
Study: NCT04641364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human albumin injection
Description: single dose or multiple doses of intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose intravenous infusion of 0.9% sodium chloride injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human albumin injection
Description: multiple doses of intravenous infusion
Study: NCT03318159

Intervention type: DRUG
Group type: OTHER
Intervention: Posaconazole
Description: Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks~\*if posaconazole tablet intolerance: posaconazole suspension 200mg tid
Study: NCT03754283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect bonding
Description: Indirect bonding is the technique where orthodontic appliances are first placed on a model of the patient and then transferred to the patient using some kinf of trays

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect bonding
Description: Indirect bonding is the technique where orthodontic appliances are first placed on a model of the patient and then transferred to the patient using some kinf of trays
Study: NCT01425190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
Study: NCT00619411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy for Depressed Adolescents & Parents
Description: 15 weekly psychotherapy sessions
Study: NCT01786616

Intervention type: DRUG
Intervention: Formoterol
Study: NCT02782663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: Tablet: Oral
Study: NCT01240122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biotrue MPS
Description: Multi-purpose contact lens care solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational MPS
Description: Multi-purpose contact lens care solution
Study: NCT02294721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard BLS
Description: Resuscitation without feedback devices, standard manual standard basic life support

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CPREazy
Description: feedback device-1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueCPR
Description: feedback device -2
Study: NCT02202525

Intervention type: DRUG
Intervention: Micardis®
Study: NCT02507726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexima Active soft convexe
Description: The Investigational Device will be used during 14 +- 3 days.
Study: NCT02202525

Intervention type: DRUG
Intervention: Other hypertensives
Study: NCT01045525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: From 300 to 400mL for women; From 350 to 450mL for men

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle and diet advices
Description: 2 Booklets with Dietary and physical activity advices
Study: NCT02398799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational support
Description: The intervention was based on a conceptual model from Stuifbergen. The model has sprung from Pender's model of health promotion and Bandura's self-efficacy theory. Cognitive-behavioral strategies were chosen to assist dyads in recognizing and modifying factors that contribute to physical and emotional distress by changing thoughts and behaviors and assisting dyads in solving problems related to implementing strategies for self-care.~Shared care is a dyadic process based on the assumption that each participant affects and is affected by the other. Shared goals and a shared commitment provide the essential building blocks of the dyad relationship. The dyad structure presents an opportunity for healthcare professionals to integrate a collaborative patient-partner centered effort.
Study: NCT00113373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02294721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CPR PRO APP
Description: feedback device -3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CardioPump
Description: feedback device- 4
Study: NCT00740779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Description: Silodosin 8 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin 4 mg
Description: Silodosin 4 mg daily